Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

142.82 +0.76 (+0.54%)
Streaming Delayed Price Updated: 9:55 AM EST, Jan 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Johnson & Johnson Buys Intra-Cellular Therapeutics In A Whopping $14.6 Billion Deal
The deal values the smaller biotech company at a 39% premium to last week's closing price. 
Via Investor's Business Daily
2 Beaten-Down Dividend Stocks to Buy in 2025
Via The Motley Fool
A Look At Dividend Kings
In this video, we dive deep into 'Dividend Kings.' These are elite companies that have consistently increased their dividends for 50+ years. 
Via Talk Markets
Topics ETFs Stocks / Equities
Stock Market Tumbles As Yields Spike; Nvidia, Tesla, Delta, Meta, Jobs Report In Focus: Weekly Review
The S&P 500 and Nasdaq are below their 50-day lines. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
4 Top Dividend Growth Stocks to Build Your Portfolio Around in 2025
These companies have track records of success, increasing dividends, and fantastic growth prospects, making them all ideal portfolio anchor stocks for a long-term investor. 
Via The Motley Fool
Smart Money Is Betting Big In JNJ Options
Via Benzinga
Johnson & Johnson Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
2 Dow Stocks to Buy Hand Over Fist in 2025 and 1 to Avoid
Among the Dow Jones Industrial Average's 30 components, there are two historically cheap brand-name companies, as well as a new member that's priced for perfection in an imperfect industry. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Johnson & Johnson Pauses US Varipulse Procedures Amid Safety Review, Investigates Brain-Related Events
Johnson & Johnson pauses U.S. Varipulse cases to investigate neurovascular events. The FDA-approved device integrates PFA therapy and 3D mapping for AFib treatment. 
Via Benzinga
J&J Falls — While Boston Scientific, Medtronic Pop — After Strokes Sideline A Key Product
The company paused sales of a key product, a rival to Boston Scientific and Medtronic, due to safety concerns. 
Via Investor's Business Daily
8 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Where to Invest $100,000 in 2025
Via The Motley Fool
Stock Of The Day: Will Johnson & Johnson Take The Market Lower?
Shares of Johnson & Johnson are flat in Monday's trading. But they continue to test support. If this support breaks, it could be bearish for the entire market. 
Via Benzinga
Neumora Therapeutics Stock Crashes 83% After Depression Drug Flops
The company said it plans to investigate a positive signal from female patients. 
Via Investor's Business Daily
10 Stock Market Predictions for 2025
Here's what to expect from the stock market, along with some of Wall Street's hottest trends and most influential businesses, in the new year. 
Via The Motley Fool
Marjorie Taylor Greene Went Christmas Shopping For Stocks, Here's What She Bought Before Holiday
Marjorie Taylor Greene spent part of Christmas Eve buying stocks according to recent disclosures. Here's what she bought. 
Via Benzinga
Dogs Of The Dow: Top 10 High-Yield Stocks Offering Dividends Up To 6.8% In 2025
In the Dow Jones Industrial Average, 28 of the 30 components pay dividends. With changes to the components in 2024, dividend yield is smaller overall. 
Via Benzinga
Topics Stocks
Exposures US Equities
Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results
Axsome's AXS-05 met endpoints in Alzheimer's agitation studies, showing long-term safety and tolerability. FDA filing planned for late 2025. 
Via Benzinga
Exposures Product Safety
5 Unbeatable Stocks I'm Eager to Buy in 2025
These value, growth, and income stocks are incredibly cheap in a historically pricey stock market. 
Via The Motley Fool
10 Dividend Stocks For Intergenerational Wealth
The Dividend Aristocrats broadly have durable competitive advantages, and long-term growth. 
Via Talk Markets
Topics Stocks / Equities
Johnson & Johnson Death Cross: Stock Stumbles Despite Pipeline Promise
Johnson & Johnson (NYSE:JNJ) enters bearish pattern, death cross, but strong dividends & strategic moves in dermatology provide long-term appeal. 
Via Benzinga
The Smartest Dividend Stocks to Buy With $1,000 Right Now
Via The Motley Fool
10 Buy And Hold Forever Dividend Stocks
The following 10 stocks represent Dividend Kings that can continue to raise their dividends for decades to come. 
Via Talk Markets
Topics Stocks / Equities
Top 7 Blue-Chip Stocks With The Best Return Potential Going Into 2025
The year 2024 saw the U.S. stock market make new records, with major indices breaching key milestones. While many stocks witnessed a stellar rally this year, analysts still expect some blue-chip... 
Via Benzinga
Give Yourself the Gift That Will Keep On Giving in 2025 and Buy These 3 Top Dividend Stocks
Via The Motley Fool
The Options Market Is Pointing Us At Four Dividend Stocks Right Now
It’s a good idea to look at stocks that can give us what we need in the absence of a rally. 
Via Talk Markets
Topics Bonds Commodities Stocks / Equities
5 Lowest Volatility Dividend Stocks
Here are five dividend-paying stocks in the S&P 500 with the lowest standard deviation of daily returns over the past five years. 
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services
U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending. 
Via Benzinga
The Smartest Dividend Stocks to Buy With $500 Right Now
Via The Motley Fool
FDA Rejects Johnson & Johnson's Injectable Version Of Approved Drug For Lung Cancer
The FDA delays Johnson & Johnson's SC amivantamab approval for NSCLC over facility inspection issues, unrelated to product safety or efficacy 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.